Cost‐effectiveness of five prenatal screening strategies for trisomies and other unbalanced chromosomal abnormalities: model‐based analysis-Reference-Cited by-同舟云学术

Cost‐effectiveness of five prenatal screening strategies for trisomies and other unbalanced chromosomal abnormalities: model‐based analysis

Published:2019-11 Issue:5 Volume:54 Page:596-603
ISSN:0960-7692
Container-title:Ultrasound in Obstetrics & Gynecology
language:en
Short-container-title:Ultrasound Obstet Gynecol

Author:

Le Bras A.¹^ORCID,Salomon L. J.²³,Bussières L.²⁴,Malan V.⁵⁶,Elie C.⁴,Mahallati H.²,Ville Y.²⁷^ORCID,Vekemans M.⁶⁷,Durand‐Zaleski I.¹⁸

Affiliation:

1. AP‐HP, DRCI‐URC Eco Ile‐de‐France Paris France

2. AP‐HP, Hôpital Necker–Enfants MaladesDepartment of Obstetrics and Gynecology Paris France

3. Collège Français d'Echographie Foetale (CFEF) France

4. AP‐HP, Hôpital Necker–Enfants Malades, Clinical Unit Research/Clinic Investigation Center Paris France

5. INSERM U1163, Hôpital Necker–Enfants Malades Paris France

6. AP‐HP, Hôpital Necker–Enfants MaladesDepartment of Histology, Embryology and Cytogenetics Paris France

7. Université Paris Descartes‐Sorbonne Paris Cité, Institut Imagine Paris France

8. Assistance Publique‐Hôpitaux de Paris, Service de Santé Publique, Henri Mondor‐Albert‐Chenevier Créteil France

Publisher

Wiley

Subject

Obstetrics and Gynecology,Radiology, Nuclear Medicine and imaging,Reproductive Medicine,General Medicine,Radiological and Ultrasound Technology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/uog.20301

Reference43 articles.

1. The maternal age-specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21 (Down syndrome)

2. HAS Haute Autorité de Santé. Place des tests ADN libre circulant dans le sang maternel dans le dépistage de la trisomie 21 fœtale. Synthèse de l'argumentaire et recommandations.https://www.has‐sante.fr/portail/upload/docs/application/pdf/2017‐05/dir42/synthese_et_recommandations__place_des_tests_adn_libre_circulant_dans_le_sang_maternel_dans_le_depistage_de_la_trisomie_21_f.pdf[Accessed April2018].

3. A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program

4. Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis

5. A cost-effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefits and harms of antenatal and newborn screening programmes in health economic assessments: the VALENTIA systematic review and qualitative investigation;HEALTH TECHNOL ASSES;2024

2. A Cost-Effectiveness Analysis of Screening Strategies Involving Non-Invasive Prenatal Testing for Trisomy 21;Frontiers in Public Health;2022-05-31

3. Incidence of chromosomal abnormalities in fetuses with first trimester ultrasound anomalies and a low‐risk cell‐free DNA test for common trisomies;Prenatal Diagnosis;2020-08-09